Vindesine in the treatment of metastatic breast cancer.

Abstract

Thirty-five patients with advanced metastatic breast cancer refractory to prior chemotherapy were treated with vindesine given at a fixed dose as a continuous 5-day infusion of 1.5 mg/day every 4 weeks. All patients were considered evaluable, and there were four patients with partial responses for more than 3 months (11%) and 13 patients with stable disease (37%). Two of the four responders had had disease progression on other vinca alkaloids. None of the responders had proven doxorubicin resistance. Side-effects included myelosuppression, neurotoxicity, nausea, stomatitis and fever, but these were seldom dose-limiting. The results--together with the results of other single-agent studies of vindesine summarized in the paper--indicate that the drug is an active agent in advanced breast cancer. However, the optimum way of administering vindesine and its inclusion in first-line therapy needs further study.

• Authors: P V Hansen, H Brincker
• Journal: European journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 20 Issue 10 Pg. 1221-5 (Oct 1984) ISSN: 0277-5379 [Print] England
• PMID: 6541581 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Phytogenic
• Vinblastine
• Vindesine

Topics

• Adult
• Aged
• Antineoplastic Agents, Phytogenic (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy)
• Drug Evaluation
• Female
• Humans
• Middle Aged
• Neoplasm Metastasis
• Vinblastine (adverse effects, analogs & derivatives, therapeutic use)
• Vindesine